Navigation Links
Susan G. Komen for the Cure Announces Recipients of 2007 Komen Brinker Award for Scientific Distinction

University of Southern California, Lawrence Berkeley National Laboratory Pioneers Honored for Prevention Studies, Widely Adopted Innovations in

Biomedical Research

DALLAS, Dec. 13 /PRNewswire/ -- Susan G. Komen for the Cure, the global leader in the movement to end breast cancer forever, has announced the recipients of the 2007 Komen Brinker Award for Scientific Distinction, the organization's highest award of merit.


This year's recipients are Leslie Bernstein, Ph.D., professor, department of preventive medicine and the inaugural holder of the AFLAC, Inc. Chair in Cancer Research at the University of Southern California, Los Angeles, and Joe W. Gray, Ph.D., director, division of life sciences, Lawrence Berkeley National Laboratory, Berkeley, Calif.

Dr. Bernstein and Dr. Gray will be formally recognized during the 30th annual San Antonio Breast Cancer Symposium (SABCS), a major international gathering of breast cancer researchers, clinicians and patient advocacy organizations, Dec. 13-16 in San Antonio. The two recipients will deliver lectures for SABCS attendees at 3:45 p.m. Dec. 13 in Exhibit Hall D of the Henry B. Gonzalez Convention Center. Both will receive cash awards of $25,000 and a crystal award.

The Art and Science of Delivering the Cures

The evening of Dec. 13, Susan G. Komen for the Cure founder Ambassador Nancy G. Brinker will be the featured speaker at a gala dinner held at the Gonzalez Center in honor of the Komen Brinker award recipients. In recognition of the art and the science involved in both research and clinical endeavors, Komen has themed the evening 'Toward a Culture of Discovery: Progress and Passion in the Search for the Cures.' Susan G. Komen for the Cure's Art for the Cure program, which features a special traveling exhibition of Ambassador Brinker's collection of Hungarian art, will be featured at the dinner event to celebrate the organizations 25th anniversary and the 15th anniversary of the Komen Brinker Award for Scientific Distinction.

The Brinker Award for Scientific Distinction was established in 1992 to honor the efforts of acknowledged pioneers in two critically important components of the fight to end breast cancer: clinical work and basic research. Since the award's establishment, the roster of Komen Brinker Award for Scientific Distinction laureates has grown to include names of researchers connected with some of the most significant advancements made in the way breast cancer is diagnosed and treated as well as the way research into the disease is conducted. This year, former Komen Brinker award laureates will also be acknowledged for their achievements.

Bernstein: Pioneer in Linking Exercise, Breast Cancer Risk

Leslie Bernstein, Ph.D., pioneered research on the link between physical activity and breast cancer, which is now well established. This research provides an evidence base for one of the few recommendations that can be made for breast cancer risk reduction. In addition to her studies on physical activity, she has contributed to the study of body size, including weight gain and obesity, another area of inquiry that has yielded insights into breast cancer risk reduction for post-menopausal women.

As director of the Los Angeles Surveillance Epidemiology and End Results (SEER) Registry, Dr. Bernstein is a leader in efforts to understand patterns in breast cancer incidence, including the troubling rise in risk among new immigrants to California. This work is fundamental to efforts in addressing breast cancer disparities and in anticipating risk among Asian-American women. Dr. Bernstein has a long and distinguished history of leadership at the University of Southern California, where she has advanced opportunities for women in science while serving as a model for the next generation of research professionals.

Dr. Bernstein will receive the 2007 Komen Brinker Award for Scientific Distinction in the category of clinical research.

Gray: Developing Technology to Solve Challenging Biomedical Problems

Joe W. Gray, Ph.D., is recognized as a pioneer in the development of innovative technologies that enable researchers to pursue original avenues of inquiry into challenging biomedical problems. The sum of his impact, innovation and creativity over the course of his career are directly linked to translational research which many leading scientists acknowledge will lead to real improvements for people living with breast cancer.

He is credited with the development and implementation of many important technologies, including high-speed sorting; flow karyotyping; the first chromosome painting probes; development of interphase fluorescent in situ hybridization (FISH); and the first demonstration using FISH showing ERBB2 amplification and BCR-ABL translocation, both of which are critically important to current patient management. His list of credits also includes brdU/DNA analysis of cell cycle progression; comparative genomic hybribidization (CGH); BAC End Sequencing (BES) and, more recently, nanotechnology.

Dr. Gray was an early adopter of technologies such as transcriptional profiling, high throughput analysis, SNP array CGH and molecular inversion probes. By integrating data received from these technologies, Dr. Gray has made significant advancements in developing methods that will lead to improved patient outcomes. Specifically, his work is leading to groundbreaking research in the determination of how to improve breast cancer detection and treatment. His efforts are helping to increase the translation of basic research to the clinic. Dr. Gray is a staunch proponent of collaborative, or "team" science. He supports an active academic-industrial collaborative enterprise to encourage industry to invest in, develop and implement technologies needed to combat breast cancer.

About Susan G. Komen for the Cure

Nancy G. Brinker promised her dying sister, Susan G. Komen, she would do everything in her power to end breast cancer forever. In 1982, that promise became Susan G. Komen for the Cure and launched the global breast cancer movement. Today, Komen for the Cure is the world's largest grassroots network of breast cancer survivors and activists fighting to save lives, empower people, ensure quality care for all and energize science to find the cures. Thanks to events like the Komen Race for the Cure, we have invested nearly $1 billion to fulfill our promise, becoming the largest source of nonprofit funds dedicated to the fight against breast cancer in the world. For more information about Susan G. Komen for the Cure, breast health or breast cancer, visit or call 1-877 GO KOMEN.

SOURCE Susan G. Komen for the Cure
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
3. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
4. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
5. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
6. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
7. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
8. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
9. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
10. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
11. CNS Response Announces Fiscal Third Quarter 2007 Results
Post Your Comments:
(Date:11/25/2015)... ... November 25, 2015 , ... Jessica Richman and Zachary ... in their initial angel funding process. Now, they are paying it forward to ... early stage investments in the microbiome space. In this, they join other ...
(Date:11/24/2015)... 2015 /CNW/ - iCo Therapeutics ("iCo" or "the Company") ... for the quarter ended September 30, 2015. Amounts, ... and presented under International Financial Reporting Standards ("IFRS"). ... said Andrew Rae , President & CEO ... not only value enriching for this clinical program, ...
(Date:11/24/2015)... -- --> --> ... Market by Product & Services (Primer, Probe, Custom Oligos, ... End-User (Research, Pharmaceutical & Biotech, Diagnostic Labs) - Global ... expected to reach USD 1,918.6 Million by 2020 from ... 10.1% during the forecast period. Browse 183 ...
(Date:11/24/2015)... TEL AVIV, Israel , Nov. 24, 2015  Tikcro Technologies Ltd. ... be held on December 29, 2015 at 11:00 a.m. Israel ... & Co., Electra Tower, 98 Yigal Allon Street, 36 th Floor, ... , election of Eric Paneth and Izhak Tamir ... and Rami Skaliter as external directors; , approval of an ...
Breaking Biology Technology:
(Date:10/29/2015)... LA JOLLA, Calif. , Oct. 29, 2015 /PRNewswire-USNewswire/ ... released a new report titled, "DNA Synthesis and Biosecurity: ... how well the Department of Health and Human Services ... was issued in 2010. --> ... advances, but it also has the potential to pose ...
(Date:10/29/2015)... BOSTON , Oct. 29, 2015  Connected health ... phenomena driving the explosion of technology-enabled health and wellness, ... his new book, The Internet of Healthy ... apps, sensors or smartphones even existed, Dr. Kvedar, vice ... model of health care delivery, moving care from the ...
(Date:10/27/2015)... YORK , Oct. 27, 2015 In ... major issues of concern for various industry verticals such ... is due to the growing demand for secure & ... in various ,sectors, such as hacking of bank accounts, ... for electronic equipment such as PC,s, laptops, and smartphones ...
Breaking Biology News(10 mins):